In a developing story, Takeda Pharmaceuticals has requested an early termination of a currently active antitrust legal proceeding. The multinational pharmaceutical company is under scrutiny with respect to delayed introduction of a generic adaptation of their gout medication — Colcrys.
Takeda contends that the existing patent disputes and an absence of substantial evidence suggesting a plot to fix prices have debilitated the argument put forth by the complainants — a consortium of drug wholesalers. This motion comes in the midst of an ongoing trial, signifying an attempt to bring a premature end to the litigation.
Legal observers and industry experts are keenly following this development considering Takeda’s place in the pharmaceutical market. Nonetheless, it is the court’s discretion that will ultimately decide the direction and the fate of this antitrust case.
For further details on the case, follow the developments on Law360.